Replimune Group, Inc.'s RP1 + OPDIVO for advanced melanoma gains FDA Priority Review. PDUFA date: July 22, 2025. Read more on ...

programmed cell death protein 1 (PD-1), vascular endothelial growth factor A (VEGFA), and cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4), which are clinically validated. It applies ...

Cadonilimab plus lenvatinib showed promising antitumor activity in patients with advanced endometrial cancer who have experienced disease progression after prior platinum-based chemotherapy,” said ...

Although recommended, many patients with metastatic clear cell RCC still don’t receive immune checkpoint inhibitor-based combinations as first-line treatment.

Key Findings: In the proof of mechanism studies, CS2009 demonstrated strong synergy between the PD-1 and CTLA-4 arms, and the checkpoint inhibitory activity from the PD-1/CTLA4 arms was also ...

Botensilimab is a human Fc enhanced CTLA-4 blocking antibody designed to ... to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies.